Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Humabs BioMed S.A.
DescriptionHuman mAb targeting all 16 types of haemagglutinin subtypes of influenza A, binding and neutralising both Group 1 and 2 human and animal viruses
Molecular Target
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentDiscovery
Standard IndicationInfluenza virus
Indication DetailsTreat influenza
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today